Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Observer-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants 18 to 65 Years of Age

NCT07737717 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT07737717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07737717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Observer-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants 18 to 65 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 31, 2026
Completion date
September 30, 2027
Enrollment
84 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ebola-bundibugyo virus disease (ebola-bdbv)